SCHEMBL2487340

SCHEMBL2487340

COc1c(CCc2ccc(NC(C)=O)cc2)cc(-c2ncc[nH]c2=O)cc1C(C)(C)C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.53
ADRA2A P08913 1/20 0.36
ADRA2C P18825 1/20 0.36
ADRA1D P25100 1/20 0.36
ADRA1A P35348 1/20 0.36
ADRA1B P35368 1/20 0.36
FGFR3 P22607 1/20 0.35
FYN P06241 2/20 0.34
NR1H4 Q96RI1 2/20 0.34
NTRK1 P04629 1/20 0.34
NTRK2 Q16620 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
TTK P33981 1/20 0.33
MAPK8 P45983 1/20 0.33
KDM4E B2RXH2 1/20 0.33
LMNA P02545 1/20 0.33
TRPV1 Q8NER1 1/20 0.33
TSHR P16473 1/20 0.33
AOC3 Q16853 1/20 0.32
ERCC1 P07992 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2487216 0.86 CYP3A4 (0.72) CYP3A4ADRA2AADRA2CADRA1DADRA1A
SCHEMBL6832645 0.85 CYP3A4 (0.51) CYP3A4ADRA2AADRA2CADRA1DADRA1A
SCHEMBL2745714 0.71 CYP3A4 (0.46) CYP3A4SMN1; SMN2LMNATRPV1MAPK14
SCHEMBL6832516 0.70 ITK (0.43) ADRA2AADRA2CADRA1DADRA1AADRA1B
SCHEMBL1542581 0.70 CYP3A4 (1.00) CYP3A4TRPV1
SCHEMBL2486477 0.68 CYP3A4 (0.55) CYP3A4
SCHEMBL1543205 0.68 CYP3A4 (0.74) CYP3A4
SCHEMBL1542866 0.68 CYP3A4 (0.73) CYP3A4KDM4E
SCHEMBL6832548 0.67 CYP3A4 (0.38) CYP3A4
SCHEMBL2491324 0.67 CYP3A4 (0.72) CYP3A4ADRA2AADRA2CADRA1DADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100158860-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS STEINER SANDRA 2010-06-24 US claimed
US-8178547-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-05-15 US disclosed
US-8178547-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-05-15 US disclosed
EP-2379534-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2011-10-26 EP disclosed
WO-2010072598-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-07-01 WO disclosed
US-20100158860-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS STEINER SANDRA 2010-06-24 US disclosed
US-20100158860-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS STEINER SANDRA 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100158860-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS RFC1, RRP1B, RRBP1 CYP3A4 978/4885ADRA2A 1156/4885ADRA2C 982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.